» Articles » PMID: 23128391

Novel BRD4-NUT Fusion Isoforms Increase the Pathogenic Complexity in NUT Midline Carcinoma

Overview
Journal Oncogene
Date 2012 Nov 7
PMID 23128391
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Nuclear protein in testis (NUT)-midline carcinoma (NMC) is a rare, aggressive disease typically presenting with a single t(15;19) translocation that results in the generation of a bromodomain-containing protein 4 (BRD4)-NUT fusion. PER-624 is a cell line generated from an NMC patient with an unusually complex karyotype that gave no initial indication of the involvement of the NUT locus. Analysis of PER-624 next-generation transcriptome sequencing (RNA-Seq) using the algorithm FusionFinder identified a novel transcript in which Exon 15 of BRD4 was fused to Exon 2 of NUT, therefore differing from all published NMC fusion transcripts. The three additional exons contained in the PER-624 fusion encode a series of polyproline repeats, with one predicted to form a helix. In the NMC cell line PER-403, we identified the 'standard' NMC fusion and two novel isoforms. Knockdown by small interfering RNA in either cell line resulted in decreased proliferation, increased cell size and expression of cytokeratins consistent with epithelial differentiation. These data demonstrate that the novel BRD4-NUT fusion in PER-624 encodes a functional protein that is central to the oncogenic mechanism in these cells. Genomic PCR indicated that in both PER-624 and PER-403, the translocation fuses an intron of BRD4 to a region upstream of the NUT coding sequence. Thus, the generation of BRD4-NUT fusion transcripts through post-translocation RNA-splicing appears to be a common feature of these carcinomas that has not previously been appreciated, with the mechanism facilitating the expression of alternative isoforms of the fusion. Finally, ectopic expression of wild-type NUT, a protein normally restricted to the testis, could be demonstrated in PER-403, indicating additional pathways for aberrant cell signaling in NMC. This study contributes to our understanding of the genetic diversity of NMC, an important step towards finding therapeutic targets for a disease that is refractory to current treatments.

Citing Articles

Transcriptomic profiling of a late recurrent nuclear protein in testis carcinoma of the lung 14 years after the initial operation: a case report.

Kato T, Oyamatsu H, Hanamatsu Y, Huang H, Okado S, Imamura Y Transl Lung Cancer Res. 2024; 13(7):1756-1762.

PMID: 39118893 PMC: 11304145. DOI: 10.21037/tlcr-24-259.


Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion.

Andreiuolo F, Ferrone C, Rajan S, Perry A, Guney E, Cham E Acta Neuropathol Commun. 2024; 12(1):42.

PMID: 38500181 PMC: 10946093. DOI: 10.1186/s40478-024-01746-7.


Histone Readers and Their Roles in Cancer.

Wen H, Shi X Cancer Treat Res. 2023; 190:245-272.

PMID: 38113004 PMC: 11395558. DOI: 10.1007/978-3-031-45654-1_8.


Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in NUT Carcinoma Harboring a Splice Site Mutation.

Cheng M, Huang Y, Luong N, Lopiccolo J, Nishino M, Sholl L JCO Precis Oncol. 2023; 7:e2200633.

PMID: 37384867 PMC: 10581614. DOI: 10.1200/PO.22.00633.


Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma.

Yu D, Liang Y, Kim C, Jaganathan A, Ji D, Han X Nat Commun. 2023; 14(1):378.

PMID: 36690674 PMC: 9870903. DOI: 10.1038/s41467-023-36063-5.